A module from the suite of health service capacity assessments in the context of the COVID-19 pandemic, Interim guidance 20 October 2020. This assessment tool covers the following aspects:
area distribution;
surface availability versus foreseen occupancy rate;
patient and staff flow...s;
ventilation requirement per specific areas;
visitors’ area and visitor flow; and
surge capacity.
more
Available in Arabic, Chinese, English, French, Russian and Spanish. You can download a summary of the main report and background documents!
The report demonstrates that the current system—at both national and international levels— was not adequate to protect people from COVID-19. The time it t...ook from the reporting of a cluster of cases of pneumonia of unknown origin in mid-late December 2019 to a Public Health Emergency of International Concern being declared was too long. February 2020 was also a lost month when many more countries could have taken steps to contain the spread of SARS-CoV-2 and forestall the global health, social, and economic catastrophe that continues its grip. The Panel finds that the system as it stands now is clearly unfit to prevent another novel and highly infectious pathogen, which could emerge at any time, from developing into a pandemic.
more
Laboratory Biossafety Manual
Laboratory Biossafety Manual
The conditionality of this recommendation is largely driven by the current higher unit cost of pyrethroid-PBO ITNs compared
to pyrethroid-only LLINs and therefore the uncertainty of their cost-effectiveness. Furthermore, as PBO is less wash-resistant
than pyrethroids, its bioavailability declines ...faster over the three-year estimated life of an ITN; therefore, the added impact of
pyrethroid-PBO ITNs over that of pyrethroid-only LLINs may decline over time. The evidence comes from two sites in
eastern Africa with pyrethroid resistance and not from other geographies where transmission levels and vector characteristics
may vary. PBO acts by inhibiting certain metabolic enzymes, primarily oxidases, and so are likely to provide greater protection
than pyrethroid-only LLINs where mosquitoes display mono-oxygenase-based insecticide resistance mechanisms.
more
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more
Objetivos: • Fornecer recomendações para as práticas de prevenção e controle de infecções (PCI) a serem usadas durante atendimento em estabelecimentos não tradicionais, no contexto da doença do novo coronavírus (COVID-19). Estas recomendações são provisórias e estão sujeitas à revi...são conforme novas evidências forem disponibilizadas. Principais considerações: • Com uma demanda crescente por leitos hospitalares, existe a necessidade de transformar estabelecimentos não tradicionais em centros de tratamento para pacientes de COVID 19 que não necessitem de hospitalização. • Para os fins deste documento, estabelecimentos não tradicionais são definidos como hotéis, motéis, abrigos, dormitórios e assistência domiciliar. Estas recomendações não se aplicam a centros de quarentena ou instituições de longa permanência para idosos. • É necessário um planejamento abrangente antes do uso de estabelecimentos não tradicionais como locais de assistência à saúde (1). Para garantir os melhores resultados possíveis, medidas de logística, segurança, gerenciamento de resíduos e controle de infecções devem ser implementadas como parte da resposta à pandemia de COVID-19.
more
Directrizes para os países
Ce document fournit des orientations provisoires sur la qualité, les caractéristiques de performance et les normes connexes des équipements de protection individuelle (EPI) à utiliser dans le contexte de COVID-19. Il s'agit notamment des dispositifs médicaux prioritaires de l'OMS, à savoir : l...es masques chirurgicaux, les masques non chirurgicaux, les gants, les lunettes de protection, les écrans faciaux, les blouses et les masques N95. Il est destiné aux organismes d'approvisionnement, aux services de santé au travail, aux services ou points focaux de prévention et de contrôle des infections, aux administrateurs d'établissements de santé, aux ingénieurs biomédicaux et des matériaux, aux fabricants d'EPI et aux autorités de santé publique, tant au niveau national qu'au niveau des établissements.
more
Note technique. Les centres de traitement de choléra fournissent des soins hospitaliers aux patients atteints de choléra
pendant les épidémies. Une prise en charge de qualité et l’isolement des patients atteints du choléra sont
essentiels pour prévenir les décès et aider à lutter con...tre la propagation de la maladie. Traditionnellement,
ces structures sont appelées centres de traitement du choléra (CTC) et unités de traitement du choléra (UTC).
Les CTC sont généralement de grandes structures mises en place au niveau central (zones urbaines, par
exemple), tandis que les UTC sont des structures plus petites, installées en périphérie (zones périurbaines ou
rurales, par exemple). Les CTC/UTC peuvent être mis en place en tant que structures indépendantes dans
des tentes ou à l’intérieur de bâtiments existants ou dans des unités sanitaires. Quelle que soit la structure,
les principes décrits dans ce document doivent être respectés.
more
Mem Inst Oswaldo Cruz , Rio de Janeiro, Vol. 110 (3): 377-386, May 2015
Ghana's attempt to regulate health care waste management started in 2002 with the development of guidelines on health care waste manage-ment by the Environmental Protection Agency (EPA). In 2006, the Ghana Health Service (GHS) also developed the Health Care Waste Management Policy and Guidelines as ...a single document.
Although awareness on Health Care Waste Management (HCWM) has improved in recent years, there is the need for a systematic approach to improve on effective segregation, safe collection, and storage, as well as ultimate treatment before disposal.
This guideline seeks to ensure that HCW is managed effectively in compliance with existing International Conventions that Ghana is a signatory to, national laws and regulations, and others to be passed in future.
Recommendations for better management of HCW in the nation's health care facilities have been presented in this document. Also, standard operating procedures (SOPs) have been developed to provide
guidance to various levels of the health facilities.
more